National Science and technology progress award list published medical industry into innovation

Recently, the national nosta released the 2009 National Science and technology award results, Zhuhai kin project imply that sails biotechnology for "national science and technology award second prize", becoming the only blood purification field has a "national science and technology progress Award" in honor of private enterprises, one filled blood purification spheres of historical blank, the overall development of the industry has an important role in the promotion and advancement.

Medical innovation, weak institutions, enterprises, scientific research investment low

It is understood that, because "the State Science and technology progress Award" authoritative, high gold content, grant object is intended for technical innovation, science and technology research and development, and so make a creative contribution of Chinese citizens and organizations, is a country on enterprise development and identity of height, represents at the same time period the latest scientific and technological development.

And medical devices and related industries and is a high investment, high-return, high-risk industry, the innovation ability of domestic enterprises generally weak.

Therefore, in the past for quite a long time, medical devices and related areas of science and technology progress award of the winners for the national research institutions and research and development strength of the institution of higher learning, medical enterprises rarely interfere.

For a long time, in the field of medical research, national research institutions has been the subject of scientific and technological innovation.

While this innovation system has its advantages, but also its disadvantages are obvious, sustainability, application of poor results, achievements into productivity capacity is low (only a small number of products in the laboratory use, formation cannot scale of industrial production). But in medical devices and related industries an application of a very strong field, most research and development work should be subject to the investment, research and development, application integration into a meet market requirements, minimize material resources, financial resources, human waste.

In fact, many developed countries in Europe and America, a high level of technological innovation has become a medical device manufacturer for maximum profits of the most fundamental reason, and because of this, companies keen to those "blockbuster"-product research and development investment.

But in our country, medical devices and related industries technology input low to represent only about 1% of sales, it and medical enterprises in developed countries for research and development investment sales ratio 15-18% in contrast to the poor.

But yet, this situation is gradually changing, more and more businesses are gradually becoming the subject of scientific and technological innovation, in the field of blood purification, China has been professionally, Zhuhai kin sail biological science is part of the representation in the enterprise.

Over the years, Ken sails follow "reform driven, market-focused, technology as the forerunner," development strategy, emphasis on technology talent introduction and training, and Sun Yat-sen University, Nankai University, the Chinese people's Liberation Army Hospital to work closely together to achieve a combination of industry, the establishment of a sound science and innovation system. And times-sponsored blood purification industry Summit Forum, promote the profession of a healthy and orderly development.

Jian Dong where indicated, General Manager of the sail, since its inception, Kin-sail every year out of the sales revenue of 10% of the investment research and technology innovation, technological innovation capabilities have been significantly improved, the core competitiveness of enterprises, enhance the value of the started to become technological innovation, creativity and innovation in the body of the application.

02-year is the first time the hemoperfusion from simple treatment of the "poisoning" of this disease can be developed for the treatment of renal failure, severe disease, psoriasis, lupus and other diseases hemoperfusion, greatly broadened hemoperfusion products use purposes, on the development of the industry has made a great history. So for the national science and technology progress award, the national authorities on our support and affirmation, and it is an inspiration and encouragement.

Currently, Kin-sail is the only domestic company which produces blood perfusion consumables and equipment for the production of blood purification of biological science and technology enterprise, is tasked with a "national 863 project," and two "national key new product project" and two "national torch plan project" scientific research tasks.

In 2007, in the State of harsh review, Kin-sail with strong technical strength, high-quality production standards become 39 first pilot by GMP inspection of medical device company, until now, Ken sail too is the only pilot by GMP inspection of blood perfusion products production enterprise.

Industry insiders said that innovation is the lifeblood of the survival and development, Enterprise only continue to increase in technology research and development investment to achieve new breakthroughs in independent innovation, trunks, invincible.

Kin-sail this was awarded "national science and technology progress Award" for China's medical industry has set a good example, also has a new enterprise for the enterprise into the Horn future development has laid a solid foundation.